Skip to content
2000
Volume 27, Issue 39
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Background: Long non-coding RNA (lncRNA) breast cancer anti-estrogen resistance 4 (BCAR4) is a characterized oncogenic lncRNA in different cancers. This review is dedicated to summarize various molecular mechanisms of BCAR4 and demonstrate that the biological functions exerted by BCAR4 are good entry points for therapy. Methods: The molecular mechanism of BCAR4 acting on tumors is summarized by reviewing PubMed. Results: The expression of lncRNA BCAR4 is abnormally increased in all kinds of tumors, including colorectal cancer, prostate cancer, bladder cancer, gastric cancer, chondrosarcoma, glioma, breast cancer, glioma, gastric cancer, liver cancer, cervical cancer, lung cancer, etc. Besides, BCAR4 mediates multiple processes involved in carcinogenesis, including proliferation, invasion, anti-apoptosis, migration. Conclusion: BCAR4 may show great clinical value in this direction as a therapeutic cancer target.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612827666210604114955
2021-11-01
2025-06-23
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612827666210604114955
Loading

  • Article Type:
    Review Article
Keyword(s): BCAR4; biomarkers; cancer; Long non-coding RNA; prognosis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test